This show promise''latest news [TPP] Teppco Q3 earnings 40C vs 44C
Exiqon Announces Positive Clinical Data From EORTC Clinical Trial Showing Oncotech EDR Assay Predicts Resistance to Platinum-Based Therapy in Ovarian Cancer
Last update: 9:11 a.m. EDT Oct. 27, 2008
VEDBAEK, Denmark, October 27, 2008 /PRNewswire-FirstCall via COMTEX/ -- The European Organization for Research and Treatment of Cancer (EORTC) has undertaken a multi-institutional prospective randomized clinical trial on 719 late stage epithelial ovarian cancer patients (named 55971). Results were announced today at the 2008 International Gynecologic Cancer Society (IGCS) biennial meeting in Bangkok, Thailand. In this study, Oncotech EDR Assays were performed on biopsies obtained from 246 patients. Results clearly demonstrate that resistance to carboplatin, as identified by the Oncotech EDR Assay, was a significant independent predictor for response to first-line treatment in advanced ovarian cancer patients.
The clinical trial results demonstrate that the use of the Oncotech EDR Assay predictive test can predict resistance to platinum-based chemotherapy before therapy is initiated. These results are important to ovarian cancer treating physicians since ovarian cancer is known to show resistance to platinum-based agents. Currently, the standard first-line treatment regimen for late stage ovarian cancer contains platinum-based chemotherapy